AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03026790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medication management
Description: Individualized management of medications for pain
Study NCT03026790 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-pharmacological pain management
Description: Individualized management of non-medication pain treatment approaches
Study NCT03026790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buprenorphine-Naloxone
Description: Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
Study NCT00800839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Starting dose of 32 mg/m\^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
Study NCT00800839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Dose of 40 mg/m\^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
Study NCT00800839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
Study NCT01514214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: WInged perimeter biliary stent insertion (Viaduct)
Description: Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
Study NCT01514214 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: traditional polyethylene stent insertion (Cotton Huibregtse)
Description: insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
Study NCT03977675 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients are assigned to one of three ketamine doses (0.3, 0.5, or 0.7 mg/kg) that will be administered intravenously.
Study NCT01579084 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AGN-199201 Vehicle
Description: AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
Study NCT04790461 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-post test
Description: Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
Study NCT02130934 — intervention group
Intervention type: PROCEDURE
Intervention: Cardiac 3D MRI
Study NCT03329287 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCBT
Description: SCBT, one hour per session.
Study NCT03329287 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SSRIs and/or SNRIs
Description: SSRIs and/or SNRIs at a recommended dosage.
Study NCT03329287 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SSRIs and/or SNRIs
Description: SSRIs and/or SNRIs at a recommended dosage.
Study NCT03329287 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Psychological Placebo
Description: Supportive and relaxation therapy, one our per session.
Study NCT02525848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: dexamethasone 8 mg iv 2 minutes before induction of anesthesia
Study NCT02525848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: oral gabapentin 600 mg 1 hour before induction of anesthesia
Study NCT02525848 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aprepitant
Description: oral aprepitan 80mg 1 hour before induction of anesthesia.
Study NCT02281799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azathioprine
Description: Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.~For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa.
Study NCT01034267 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F2695 SR
Description: Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
Study NCT03176420 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angioplasty and stenting of occluded cervical ICA
Description: The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
Study NCT01459432 — intervention group
Intervention type: OTHER
Intervention: Venepuncture and blood sample collection.
Description: Venepuncture and blood sample collection.
Study NCT01452633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.25% bupivicaine will be injected at the study port site prior to incision
Description: Injection will precede the incision
Study NCT01452633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivicaine will be injected at the study port site prior to incision
Description: Injection will precede the incision
Study NCT01452633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline will be injected at the study port site prior to incision
Description: Injection will precede incision
Study NCT01452633 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline will be in injected into the port site prior to closure
Description: Saline will be injected into the port site prior to the closure without any preincisional intervention
Study NCT01452633 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.25% bupivicaine will be injected into the port site prior to closure
Description: 0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
Study NCT03044483 — intervention group
Intervention type: OTHER
Intervention: Measurement of sublingual microcirculatory parameters
Description: Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
Study NCT01615107 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COOK RIPENENIG BALLOON+PITOCN
Description: GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
Study NCT01615107 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PITOCIN
Description: : Oxytocin infusion alone (Standard Protocol
Study NCT01726881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal stimulation
Description: Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel.
Study NCT01726881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal stimulation
Description: Stimulation using a Thermal Sensory Analyzer:~2001, Maddock ltd., Israel.
Study NCT01726881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical stimulation
Description: Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
Study NCT01726881 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical stimulation
Description: Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
Study NCT01726881 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulator (TENS)
Description: A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
Study NCT00155389 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Helicobacter pylori eradication
Description: For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.~The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013.
Study NCT05017922 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization combined with endoscopic therapy
Description: TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
Study NCT05017922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: transarterial chemoembolization combined with endoscopic therapy
Description: TACE: The tip of the catheter was advanced into tumor-feeding artery based on the tumor location and size. 5-Fu was injected. Then the chemolipiodolization was performed, using oxaliplatin, epirubicin and lipiodol. If stagnant flow did not realized, then injected pure lipiodol. If the tumor-feeding artery still cannot be completely embolized, several absorbable gelatin sponge particles would be injected. Endoscopic therapy: After the site of esophageal varices was identified by the gastroscopy, spiral ligation using the EVL device (COOK, MBL-6-F) was performed and ensure the varices were fully inhaled, 1-3 rubber bands were used totally. After EVL, water was sprayed to the ligation sites to check for bleeding. If gastric varices were found, EIS was performed using the 'sandwich method' of hypertonic glucose-tissue adhesive-normal saline. Make sure the needle entered the varieose vein before inject drugs, and repeated the injection if necessary.
Study NCT02331381 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging
Study NCT01829438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to fast music
Study NCT01829438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to preferred music
Study NCT01829438 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Listening to slow music
Study NCT05011968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lettuce with not biofortification
Description: Lettuce without any biofortification was assigned to each participant belonging to the control group which ate 100gr every day for 10 days
Study NCT05011968 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lettuce biofortificated with Iodine
Description: Lettuce with Iodine biofortification was assigned to each participant belonging to the intervention group which ate 100gr every day for 10 days
Study NCT01605929 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Retroclavicular Brachial Plexus Block and Catheter Insertion
Description: A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
Study NCT03751631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide 1%-Phenylephrine 2.5% ophthalmic solution (TR/PE)
Description: Fixed combination tropicamide 1%-phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Study NCT03751631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tropicamide 1% ophthalmic solution (TR)
Description: Tropicamide 1% ophthalmic solution administered with the Optejet microdose dispenser
Study NCT03751631 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Phenylephrine 2.5% ophthalmic solution (PE)
Description: Phenylephrine 2.5% ophthalmic solution administered with the Optejet microdose dispenser
Study NCT01615107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: double balloonand oxytocin
Description: balloonand oxytocin
Study NCT01615107 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ballon and oxytocin
Description: double- balloon catheter device with concurrent oxytocin
Study NCT01615107 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: double balloonand and oxytocin
Description: balloon catheter device with concurrent oxytocin
Study NCT02133183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02133183 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT02133183 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sapanisertib
Description: Given PO
Study NCT04790461 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pre-post test
Description: Adult Caregiver Quality of Life Questionnaire (AC-QoL) Perceived Stress Scale (PSS) The Stress Coping Styles Questionnaire (SCSQ)
Study NCT04790461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face training + PMR exercise
Description: 4 weeks Roy adaptation-based face-to-face training + PMR exercises to be taught, 4 weeks exercise counseling
Study NCT04790461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mobile health education + PMR exercise
Description: To provide awareness and exercise with 8 weeks Roy adaptation model-based training and mobile application access with PMR exercise content
Study NCT04790461 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: face-to-face and mobile health education + PMR exercise
Description: 4 weeks face-to-face training based on Roy adaptation model + teaching PMR exercises and 4 weeks based training on Roy adaptation model and mobile application access with PMR exercise content
Study NCT01186692 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Melody® Transcatheter Pulmonary Valve
Description: Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
Study NCT04238026 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal radial artery approach
Description: Use of distal radial artery approach in coronary angiography and angioplasty
Study NCT04238026 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal radial artery approach
Description: Use of distal radial artery approach in coronary angiography and angioplasty
Study NCT02937961 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Early SLED
Description: withing 6 to 12 hours
Study NCT02937961 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Late SLED
Description: when absolute indications will meet
Study NCT02508467 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fisogatinib (BLU-554)
Study NCT03949166 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: food during labor and delivery
Description: The food that will be allowed during labor and delivery was approved by the anesthesia team. It includes - fruits, energy bars, yogurt,
Study NCT03224182 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Qapzola
Description: Qapzola administered by the intravesical route.
Study NCT03224182 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Qapzole-matching placebo administered by the intravesical route.
Study NCT02672254 — intervention group
Intervention type: RADIATION
Intervention: Samples with 2 treatments
Description: Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
Study NCT01176487 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Study NCT01176487 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT01176487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-dimensional conformal radiation therapy
Study NCT02455700 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Interproximal Enamel Reduction
Description: removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
Study NCT01176487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: palliative radiation therapy
Study NCT01176487 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: whole-brain radiation therapy
Study NCT01886456 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser trabeculoplasty
Study NCT01886456 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser trabeculoplasty
Study NCT02798068 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Solu-medrol or placebo administration
Description: patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
Study NCT02798068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Solu-medrol or placebo administration
Description: patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
Study NCT00873951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intestinal and metabolic exploration
Description: Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
Study NCT02120027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibodutant 10 mg
Description: Oral tablet, to be given once daily.
Study NCT02120027 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
Study NCT03192605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blueberry
Description: Blueberry - 150 grams wild blueberries (whole fruit)
Study NCT03192605 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo - matched for calories and fiber
Study NCT02328833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental strategies of guidelines implementation
Description: Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
Study NCT00873951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15N-labelled intact casein
Description: standard mixed meal containing 15% of energy as 15N-labelled intact casein
Study NCT00873951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 15N-labelled hydrolyzed casein
Description: standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
Study NCT00873951 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mixture of AA
Description: standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
Study NCT02919475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JTE-051
Description: Active drug tablets containing JTE-051
Study NCT02919475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablets identical in appearance to the active drug tablets
Study NCT00608205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cisplatin
Description: Given IV
Study NCT00608205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Given IV
Study NCT00608205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02701985 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching-placebo capsules will be administered orally, 2 times a day with food.
Study NCT02701985 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO5459072
Description: RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
Study NCT01351298 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride
Description: Decongestant with local anesthetic